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Clinical implications of heterogeneity in PD-L1
immunohistochemical detection in hepatocellular
carcinoma: the Blueprint-HCC study
David J. Pinato1, Francesco A. Mauri1, Paolo Spina2,3, Owen Cain4, Abdul Siddique1, Robert Goldin1, Stephane Victor1, Corinna Pizio3,
Ayse U. Akarca5, Renzo L. Boldorini3, Luca Mazzucchelli2, James R. M. Black1, Shishir Shetty4, Teresa Maraﬁoti5 and Rohini Sharma1
Programmed cell death ligand-1 immunohistochemical detection (PD-L1 IHC) is a putative predictor of response to PD-1/PD-L1-
targeted checkpoint inhibitors. However, there is no gold standard assay in hepatocellular carcinoma (HCC). We evaluated 5 PD-L1
IHC assay platforms (E1LN3, 28-8, 22c3, SP263 and SP142) in 100 HCCs reporting PD-L1 expression in malignant (M) and tumour-
inﬁltrating immune cells (TICs) and non-tumorous cirrhotic tissues (NTICs). We found substantial inter-assay heterogeneity in
detecting PD-L1 expression in M (R2= 0.080–0.921), TICs (Cohen’s κ= 0.175–0.396) and NTICs (κ= 0.004–0.505). Such diversity may
impact on the reliability and reproducibility of PD-L1 IHC assays as a predictor of response to immune checkpoint inhibitors.
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BACKGROUND
Immune evasion through up-regulation of programmed cell
death-1 (PD-1) pathway is a pivotal mechanism in the progression
of hepatocellular carcinoma (HCC), a disease characterised by
dismal prognosis and limited treatment options. Therapeutic
reversal of immune exhaustion with anti-PD-1/programmed cell
death ligand-1 (PD-L1)-targeted therapies induces responses in
only 20% of patients with HCC.1
PD-L1 expression by immunohistochemistry (IHC) enriches for
response to immune checkpoint inhibitors (ICPIs) in selected
tumours.2 However, its utility in HCC remains controversial.
Albeit its expanding clinical use, the predictive role of PD-L1 IHC
status is limited by analytical variability, a factor that can be
potentially controlled by standardisation of PD-L1 protein
detection techniques in clinical samples. Compelling evidence
in non-small-cell lung cancer (NSCLC) and melanoma suggests
signiﬁcant inter-assay heterogeneity in comparative studies of
PD-L1 IHC tests due to geographical heterogeneity in PD-L1
expression, antibody used and interpretation.3,4 While consider-
able research efforts are underway to harmonise PD-L1 IHC
assays in other solid tumours,5 the performance of the various
PD-L1 IHC assays available is unknown in HCC. As a result, no
recommendation can be made for an optimal PD-L1 IHC test in
HCC, a tumour where PD-L1 expression predicts for adverse
prognosis, but whose predictive role in deﬁning an increased
likelihood of response to ICPI remains unclear.6 To address this
issue, in Blueprint-HCC we performed a quantitative comparison
of ﬁve antibody clones used for PD-L1 IHC testing in landmark
trials of ICPI.
METHODS
We constructed tissue microarrays (TMAs) using a multi-centre
repository of 100 archival HCC specimens from three tertiary
referral centres including Imperial College London (UK, n= 41),
the academic Liver Unit in Birmingham (UK, n= 20) and Novara
(Italy, n= 39) following ethical approval (Ref. 17/YH/0015).
Patients were treated between 2001 and 2016 and clinicopatho-
logic features are presented in Table S1. None of these patients
received ICPI therapy. PD-L1 IHC (Fig. S1) with antibody clones
E1LN3, 28-8, 22c3, SP263 and SP142 was performed in triplicate
cores from tumour (Fig. 1a) and background liver. In tumour cores,
PD-L1 expression was evaluated in malignant (M) and in tumour-
inﬁltrating immune cells (TICs). In non-tumorous cores, we
reported the presence and intensity of immunopositivity of
inﬁltrating cells (NTICs).
PD-L1 expression was scored in M samples as the percentage of
immune-positive cells (1% cut-off) multiplied by chromogenic
intensity (ranked from 0 to 3) to derive a semi-quantitative H-
score.7 For immune inﬁltrates, PD-L1 positivity was scored semi-
quantitatively in a four-tiered system (0–3). Analysis was
performed using PRISM (GraphPad, La Jolla, CA, USA). Pearson’s
correlation coefﬁcient and Cohen’s κ were utilised to evaluate the
inter-assay agreement in deﬁning the heterogeneity of PD-L1
expression.3
RESULTS
Tumoral PD-L1 expression was lowest for E1L3N (2%, mean H-
score 0.4, standard deviation [SD] 4.0), followed by SP263 (5%,
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Fig. 1 a Representative serial tissue microarray (TMA) sections showing patterns of programmed cell death ligand-1 (PD-L1) immunopositivity
using E1L3N, 22c3, 28-8, SP263 and SP142 antibodies. Original magniﬁcation ×200. b Distribution of PD-L1 expression (H-score) in malignant
cells across the studied PD-L1 immunohistochemical (IHC) assays in 100 patients with hepatocellular carcinoma (HCC). c Pearson’s correlation
coefﬁcients for the comparison of H-scores in malignant cells across the studied PD-L1 IHC assays. d The proportion of PD-L1-expressing
immune cells inﬁltrating tumour tissue (TIC, n= 100). e The proportion of PD-L1-expressing immune cells inﬁltrating the cirrhotic peritumoral
tissue (NTIC, n= 100)
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mean H-score 0.9, SD 12.4), 22c3 (9%, mean H-score 2.0, SD 12.1),
28-8 (10%, mean H-score 6.0, SD 18.9) and SP142 (13%, mean H-
score 2.0, SD 12.4) (Fig. 1b). In total, 71 cases were PD-L1-negative
expression by all tested antibodies. Prevalence of PD-L1-positive
TIC was 6% for E1L3N, 22% for 22c3, 18% for 28-8, 14% for SP263
and 13% for SP142. PD-L1-positive NTIC rate was 2% for E1L3N,
18% for 22c3, 19% for 28-8, 13% for SP263 and 5% for SP142.
Despite good staining reproducibility between M triplicates
(Table S2), pairwise comparison of H-scores across different
antibodies revealed substantial heterogeneity, with highest
concordance between E1L3N/SP142 (R2= 0.921) and lowest
between SP263/28-8 (R2= 0.080) (Fig. 1c). Low level of con-
cordance persisted when PD-L1-negative cases were excluded
(Table S3). We compared the capacity of each antibody to detect
PD-L1-positive immune inﬁltrates by dichotomising negative cases
(score 0) against samples scoring positive for PD-L1 expression at
any intensity (scores 1–3). We report signiﬁcant inter-assay
variability in proportion and intensity of PD-L1 expression in
immune cell inﬁltrates (Fig. 1d, e, Fig. S2–3). Cohen’s κ testing
revealed the greatest level of inter-assay discordance in NTIC
versus TIC, suggesting geographical variation as a potential
determinant inﬂuencing the heterogeneity of PD-L1 expression
in HCC (Table 1). No association between PD-L1 positivity and
disease characteristics was found (Table S4).
DISCUSSION
In Blueprint-HCC we document signiﬁcant inter-assay variability in
tumoral and stromal immunolabelling across the principal anti-
body clones utilised for PD-L1 IHC testing in clinical trials and
routine practice. Our observation mirrors the results generated in
melanoma and NSCLC, where a number of companion diagnostic
assays have evolved in parallel with the clinical development of
PD-1/PD-L1-targeting ICPI.8 Compared to other tumours, however,
the level of inter-assay heterogeneity observed in HCC samples
appears even more substantial. Unlike melanoma and NSCLC, HCC
is unique for the presence of an immune cell-rich cirrhotic
microenvironment, which adds a further layer of complexity to the
classiﬁcation of PD-L1 status. To address spatial and cellular
heterogeneity in PD-L1 immunolabelling, we ensured representa-
tion of multiple cores from the centre, periphery of HCC and the
cirrhotic microenvironment. With this approach, we were able to
discover substantial heterogeneity in PD-L1 immunolabelling of
immune cell inﬁltrates, which was maximal for NTIC (Cohen’s κ
range 0.004–0.505) compared to TIC (0.175–0.396). This is not the
ﬁrst report to suggest the relevance of spatial variance as a
determinant of PD-L1 IHC status in malignancy, a ﬁnding that
might explain the suboptimal linkage between PD-L1 expression
and response to PD-1/PD-L1-targeting ICPI. Despite the potential
for underestimation in determining PD-L1 status due to the focal
nature of protein expression in malignant and immune cells, the
use of serial TMA sections might have facilitated a more
standardised and less subjective evaluation of cancer specimens
as shown in previous studies.9 Moreover, in the clinic, the issue of
sampling bias is unavoidable as PD-L1 status requires evaluation
in biopsy samples, where the quantity of tissue is limited and not
dissimilar to that available in a standard TMA section.
Methodologically, the PD-L1 IHC results reported here have
been generated using standardised antigen retrieval, immunos-
taining and scoring techniques, in an attempt to mitigate
potential sources of bias. Importantly, there were no qualitative
differences in the staining pattern produced by any of the tested
antibodies, all of which reproduced the speciﬁc staining patterns
in the tested samples comparable with those of appropriate
positive control reactions.
Based on our ﬁndings, the heterogeneity of PD-L1 IHC assays
does not appear dependent on the portion of the PD-L1 protein
recognised by the tested antibody. When considering immunos-
taining in M cores, we did not observe signiﬁcant differences
between the antibodies targeting the extracellular (E1LN3, 22c3,
28-8) versus the intracellular domain (SP263, SP142), a ﬁnding of
clinical importance due to the existence of diverse splicing
variants of PD-L1 with uncertain biologic signiﬁcance, which might
have been differentially captured by each antibody.10
To conclude, in the Blueprint-HCC study we have shown
signiﬁcant heterogeneity in the performance of PD-L1 IHC assays
in HCC. Whether depending on target epitope diversity, differ-
ential assay speciﬁcity or antibody afﬁnity, our study highlights
inter-assay variation to be a critical component of the reliability
and reproducibility of PD-L1 expression as a predictive correlate of
response to immunotherapy. None of the patients identiﬁed in
this study have received ICPI treatment for HCC; therefore, we
cannot infer a relationship between PD-L1 IHC heterogeneity and
response to immunotherapy. Prospective studies evaluating the
diverse PD-L1 IHC assays in patient cohorts with adequate linkage
with outcomes from PD-1/PD-L1 ICPI treatment are urgently
warranted to clarify the clinical meaning of such variation and
facilitate patient selection for immunotherapy.
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Table 1. Inter-assay agreement evaluated by Cohen’s κ coefﬁcient in
deﬁning the presence of a PD-L1-positive TIC and NTIC in patients
with hepatocellular carcinoma (n= 100)
E1L3N 22c3 28-8 SP263 SP142
PD-L1+ TIC
E1L3N – 0.211 0.175 0.235 0.209
22c3 0.222 – 0.313 0.396 0.222
28-8 0.175 0.313 – 0.257 0.199
SP263 0.235 0.263 0.257 – 0.267
SP142 0.209 0.222 0.199 0.267 –
PD-L1+ NTIC
E1L3N – 0.038 0.061 0.036 0.030
22c3 0.038 – 0.169 0.505 0.086
28-8 0.061 0.169 – 0.111 0.004
SP263 0.036 0.505 0. – 0.041
SP142 0.030 0.086 0.004 0.41 –
TIC immune inﬁltrate in tumour, NTIC immune inﬁltrate in cirrhosis
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